Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 9Rituximab 6Tacrolimus 5Busulfan 5fludarabine phosphate 4blinatumomab 4Vincristine 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4fludarabine 3Whole-Body Irradiation 3Valganciclovir 3Everolimus 3venetoclax 2dacetuzumab 2cobomarsen 2Thiotepa 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Filgrastim 2Epoetin Alfa 2Antilymphocyte Serum 2sargramostim 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoproliferative Disorders × Biological Assay × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡